Section Arrow
CHRS.NASDAQ
- Coherus BioSciences
Quotes are at least 15-min delayed:2024/05/16 11:22 EDT
Last
 2.125
-0.055 (-2.52%)
Day High 
2.21 
Prev. Close
2.18 
1-M High
2.3219 
Volume 
377.19K 
Bid
2.12
Ask
2.13
Day Low
2.12 
Open
2.15 
1-M Low
1.81 
Market Cap 
250.10M 
Currency USD 
P/E -- 
%Yield
10-SMA 2.15 
20-SMA 2.1 
50-SMA 2.24 
52-W High 5.63 
52-W Low 1.4301 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.74/0.19
Enterprise Value
728.80M
Balance Sheet
Book Value Per Share
-0.71
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
257.24M
Operating Revenue Per Share
1.84
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SCPXScorpius Holdings0.0994+0.0217+27.93%-- 
JAGXJaguar Health0.2669+0.0118+4.63%-- 
DNAGinkgo Bioworks Holdings0.828-0.0111-1.32%-- 
NVAXNovavax12.86-0.04-0.31%-- 
NBYNovaBay Pharmaceuticals0.1009-0.0036-3.44%-- 
Quotes are at least 15-min delayed:2024/05/16 11:22 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.